Clinical trial
Timed-Sequential Induction in CBF-AML
NCT00428558 · Assistance Publique - Hôpitaux de Paris, Other · Completed
Key facts
| NCT number | NCT00428558 |
|---|---|
| Title | Timed-Sequential Induction in CBF-AML |
| Official title | A Phase 3 Trial of Systematic Versus Response-adapted Timed-Sequential Induction in Patients With Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) |
| Lead sponsor | Assistance Publique - Hôpitaux de Paris, Other |
| Collaborators | Acute Leukemia French Association French Innovative Leukemia Organisation |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Acute Myeloid Leukemia |
| Intervention type | Drug |
| Interventions | Chemotherapy (DAUNORUBICINE-CYTARABINE) |
| Enrollment | 200 |
| Start date | Jul 1, 2007 |
| Primary completion | Jun 1, 2011 |
| Completion | Jun 1, 2011 |
| First posted | Jan 30, 2007 |
| Last update posted | Dec 20, 2013 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: